FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 03:46:20 2024-07-16 am EDT | ||
| 15.74 EUR | +0.64% |
|
| Current month | +23.44% | ||
| 1 month | +6.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 15.74 | +0.64% |
| 24-07-15 | 15.64 | +4.06% |
| 24-07-12 | 15.03 | -3.28% |
| 24-07-11 | 15.54 | +1.70% |
| 24-07-10 | 15.28 | +4.23% |
Real-time BOERSE MUENCHEN
Last update July 16, 2024 at 03:46 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD33L5 |
| ISIN | DE000HD33L55 |
| Date issued | 2024-02-27 |
| Strike | 409.2 $ |
| Maturity | Unlimited |
| Parity | 5.24 : 1 |
| Emission price | 10.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.16 € |
|---|---|
| Lowest since issue | 4.72 € |
| Spread | 0.16 € |
| Spread % | 1.00% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
490.8
USD
Average target price
473.1
USD
Spread / Average Target
-3.62%
- Stock Market
- Certificates
- Certificat
